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Objective: Nitric oxide has been reported to reduce intimal hyperplasia as a
response to arterial injury. This study was designed to assess the possible
effect of perivascular application of a nitric oxide donor on neointimal
proliferation occurring in veins exposed to the dynamics of the arterial
circulation in a hypercholesterolemic rabbit model. Methods: Autologous
jugular vein grafts were implanted in the carotid circulation of 20 hyper-
cholesterolemic rabbits. A mixture of a biodegradable polymer and the
nitric oxide donor, spermine/nitric oxide, which releases nitric oxide with a
half-life of 39 minutes, was applied periadventitially at the time of
implantation. Controls were veins bathed in saline solution, polymer alone,
and polymer plus the carrier vehicle spermine without nitric oxide. Animals
(n 5 5 in each group) were put to death on day 28 for morphometric
analysis, cell count, and immunohistochemical staining. Results: Treatment
with perivascular nitric oxide donor significantly decreased wall thickness
(126 6 24 mm vs 208 6 45 mm, p 5 0.0017) and area (124 6 22 mm2/mm
vs 211 6 37 mm2/mm, p 5 0.005). With the carrier vehicle spermine alone,
there was a trend toward reduced intimal thickness, but the change was not
statistically significant. In the grafts treated with nitric oxide donor,
expression of insulin-like growth factor, fibroblast growth factor, throm-
bospondins, fibronectin, and tenascin was reduced. Conclusion: The peri-
adventitial delivery of nitric oxide donor produces a reduction of neointimal
hyperplasia in veins implanted in the arterial circulation. The mechanism
of action is not entirely clear, but the reduction cannot be explained on the
basis of decreased cell proliferation alone. Other possibilities are modulation
of protein synthesis of vascular smooth muscle cells and production of
extracellular matrix components. (J Thorac Cardiovasc Surg 1998;115:604-14)
Vein grafts continue to be commonly used asbypass conduits for occluded arteries. Initial
patency rates are in the 80% to 90% range during
the first year but decline to around 50% at 10 years.1
This decline is apparently related to injury that
occurs as a consequence of the venous exposure to
arterial hemodynamic conditions, including overdis-
tention, higher intraluminal pressure, and increased
sheer stress forces associated with elevated flow
velocities. Changes resulting from vascular injury
and factors that could lead first to intimal prolifer-
ation and then to arteriosclerosis have been exten-
sively studied in arterial as well as venoarterial
animal models.2-6 Methods to moderate these
changes, including the role of nitric oxide (NO),
previously referred to as endothelium-derived relax-
ing factor, in modulating these changes, have been
much more extensively studied in arteries than in
veins.7, 8 In these arterial models, NO released
luminally by endothelial cells decreases platelet
adhesiveness and aggregation.9 NO has also been
shown to be an important modulator of neutrophil
interaction with the endothelium10 and of vascular
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smooth muscle cell mitogenesis and proliferation.11
The effects of NO on smooth muscle protein syn-
thesis and modulation of extracellular matrix are
less well known.
The present investigation was designed to study
the less well-defined effects of NO delivered to the
perivascular tissues of veins exposed to the dynamics
of the arterial circulation. To meet this goal, we
achieved perivascular delivery of NO by mixing the
NO donor, spermine/NO that releases NO with a
half-life of 39 minutes, with a biodegradable poly-
mer (Atrigel copolymer of polylactic and polygly-
colic acid, Comedicus, Inc., Columbia Heights,
Minn.). The polymer was applied perivascularly
around the vein at the time of implantation into the
arterial carotid circulation of New Zealand White
rabbits. The effects of perivascular delivery of NO
donor on the development of neointima, cell prolif-
eration, and the expression of growth factors and
extracellular matrix proteins in venoarterial grafts
were examined. Suppression of neointimal hyper-
plasia by NO donors could potentially improve the
patency and prolong the useful life of venoarterial
grafts.
Methods
Animal model. Autologous jugular vein grafts were
implanted in the common carotid artery of 20 hypercho-
lesterolemic New Zealand White rabbits weighing be-
tween 3 and 3.5 kg. All animals were anesthetized with
ketamine (4 mg/kg) and xylazine (2 mg/kg), which was
mixed and given as a bolus intravenous injection. Anes-
thesia was maintained with an intravenous solution con-
taining 200 mg of ketamine and 40 mg of xylazine in 250
ml of normal saline solution. After systemic hepariniza-
tion, the external jugular vein was exposed on one side of
the neck, removed, and flushed with heparinized saline
solution. The carotid artery was exposed, and after control
of flow was obtained by clamping proximally and distally,
the vein segment was reversed and end-to-side anastomo-
ses were performed with the aid of surgical magnification
and continuous 8-0 polypropylene sutures. The carotid
artery was tied close to the proximal and distal anastomo-
ses and divided in between to direct all of the carotid flow
through the vein graft. The average length of the grafts
was 3 cm. Animals were fed 2% cholesterol diets starting
1 week before the operation and continuing throughout
the duration of the experiment.
The animals were divided into four groups of five
rabbits each. In the first group, the vein was bathed in
saline solution before implantation (saline control). In the
second group, the biodegradable polymer was used to
cover the vein entirely immediately after implantation
(polymer control). In the third group, the vein was
covered after implantation with a mixture of the polymer
and the carrier spermine (spermine control). In the fourth
group, the NO donor (spermine/NO) mixed with the
biodegradable polymer was applied all around the im-
planted vein graft. On postoperative day 28, animals were
anesthetized as described earlier; the grafts were dissected
and removed together with segments of carotid artery
attached proximally and distally. After being flushed with
heparinized saline solution, the distal segment of the
artery was tied and the graft was distended with 4%
paraformaldehyde until the diameter was the same as in
vivo. The proximal portion of the artery was then tied and
the graft was immersed in 4% paraformaldehyde for 1
hour. The tissue was then removed from the paraformal-
dehyde, washed with a solution of 20% sucrose, and kept
immersed in the same solution at 4° C for 12 to 14 hours.
Specimens were then transferred to 10% paraformalde-
hyde for 8 hours and into 70% alcohol before they were
embedded in paraffin blocks. Animal care complied with
the “Principles of Laboratory Animal Care” formulated
by the National Society of Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
issued by the National Institutes of Health (U.S. Depart-
ment of Health and Human Services, NIH Publication
No. 86-23, revised 1985).
Morphometry. In the rabbit, the normal external jugu-
lar vein stained with hematoxylin and eosin has a very
fragmented and difficult-to-visualize internal elastic lam-
ina and a very thin wall (Fig. 1, A). It is virtually impossible
to separate the intima from the media, which together
have a small mass, and thereby obtain accurate measure-
ments of each. Consequently, we measured the “prolifer-
ative zone,” composed of these two layers, to obtain
thickness (micrometers), luminal and neointimal circum-
ference, as well as neointimal area (square micrometers
per micrometer). These values were obtained by means of
a calibrated, computer-based, image-measuring software
system (Optimas, BioScan, Inc., Edmonds, Wash.), as
described by us previously.12 The same computerized
system was used to count cells with a light microscope at
203 magnification (cells per square millimeter) after
nuclear staining with hematoxylin.
Immunohistochemical staining. Paraffin-embedded
sections (4 mm in thickness) of vein graft specimens were
deparaffinized in xylene, rehydrated in decreasing concen-
trations of alcohol, washed in water, and then submerged
in phosphate-buffered saline solution (PBS, Sigma Chem-
ical Co., St. Louis, Mo.) for 15 minutes. Tissue sections
were washed with PBS and digested with 0.4% trypsin
(Sigma) for 15 minutes at room temperature. After being
washed with PBS, the sections were blocked by 2% horse
serum (Vector Laboratories, Inc., Burlingame, Calif.) in
PBS containing 1% bovine serum albumin (BSA, Sigma),
or 3% BSA in PBS (thrombospondin only) for 30 minutes
at room temperature. The tissue sections were then
incubated overnight at 4° C with monoclonal antibodies
(10 gm/ml) to insulin-like growth factor I (Upstate Bio-
technology, Inc., Lake Placid, N.Y.), fibroblast growth
factor I (Upstate Biotechnology, Inc.), thrombospondin
(Immunotech, Inc., Westbrook, Maine), fibronectin
(Chemicon International, Inc., Temecula, Calif.), and
tenascin (Chemicon). The second incubation was in bio-
tinylated antimouse immunoglobulin G or antirat immu-
noglobulin G antibodies (Vector), diluted 1:400 in PBS
for 30 minutes at room temperature, and streptavidin
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conjugated with alkaline phosphatase in PBS (DAKO
Corp., Carpinteria, Calif.) for 30 minutes at room tem-
perature. Signal was developed by means of a fuchsin
substrate system (DAKO). The sections were counter-
stained with dilute hematoxylin. Unrelated antigen-spe-
cific antibody (mouse immunoglobulin G, negative control
from DAKO Corporation) and normal rat serum were
used for primary antibody control.
The different intensities of the stain were graded indepen-
dently by two of the authors (M.C.F. and Y.O). The neoin-
tima and the adventitia were graded separately by means of
a semiquantitative scale from 0 (negative stain) to 3 (diffuse,
intense stain); a grade of 1 was given to focal, mild staining
and a grade of 2 to multifocal, moderate staining.
Statistical analysis. Data are presented as mean 6
standard deviation. The analysis of variance using the
Bonferroni multiple comparison was performed to deter-
mine which two groups were different from each other;
the adjusted p value for the required six comparisons
should be 0.008 (a 5 0.05/6).
Fig. 1. Sections from normal vein (A), venoarterial graft bathed in saline solution (B), graft covered with
polymer only (C), graft covered with polymer1spermine (D), and graft covered with polymer1spermine1
NO (E). a, Adventitia; n, neointima media and intima, or proliferative zone. Arrowheads, Epithelial cells.
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Results
The 2% cholesterol diet was well tolerated. With
this concentration of cholesterol in the diet, serum
levels rise rapidly and are maintained at values of
more than 1000 mg/dl.
All venoarterial grafts in the different groups of
animals remained open when the animals were
killed, and all had some degree of intimal hyperpla-
sia. Perivascular delivery of spermine/NO using a
mixture of a biodegradable polymer resulted in a
significant decrease in neointimal thickness and area
compared with the saline control group (126 6 24
mm vs 208 6 45 mm ([p 5 0.0017] for thickness and
124 6 22 mm2/mm vs 211 6 37 mm2/mm [p 5 0.005]
for area) or the polymer control group (126 6 24
mm vs 205 6 23 mm [p 5 0.0023] for thickness and
124 6 22 mm2/mm vs 204 6 27 mm2/mm [p 5 0.0011]
for area) (Fig. 2). With the polymer mixed with the
carrier spermine alone, there was a trend toward a
reduction in neointimal formation, but the effect did
not achieve statistical significance when compared
with saline or polymer only controls. The inhibitory
effects of polymer1spermine were not significantly
different from those caused by polymer1spermine/NO
(Fig. 2). Microscopically, the grafts continued to have
a single layer of endothelial cells, beneath which were
layers of smooth muscle cells interspaced with inter-
cellular matrix (Fig. 1). There was a trend toward a
reduction in the number of cells per square millimeter
in NO-treated animals (3179 6 799) as compared with
the saline (4542 6 614), polymer (4193 6 986), and
spermine (4057 6 754) controls, although the differ-
ences were not enough to achieve significance (p 5
0.08) when tested by means of the Bonferroni modifi-
cation for multiple comparisons (Fig. 3). We believe
that the decrease in cell numbers is not enough to
account for the total differences in thickness and area
among all groups; consequently, the reduction of ex-
Fig. 2. A, Bar graphs showing the effects of the NO donor (group 4), spermine/NO (group 3), on mean
cross-sectional neointimal thickness. B, Mean cross-sectional neointimal area, as compared with saline
control (group 1) and polymer alone (group 2).
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tracellular matrix becomes an important factor in
explaining this phenomenon. The extracellular matrix
components studied by immunohistochemical staining
were reduced in the NO donor–treated grafts; this
reduction was more significant for thrombospondins
(1 6 0.5 vs 3 6 0.5) (Fig. 4) and less so for fibronectin
(1 6 0.5 vs 2 6 0) and tenascin-A (1 6 0.2 vs 2 6 0.2).
Of the two growth factors studied, expression of insu-
lin-like growth factor I was significantly reduced by
NO donor administration (0.6 vs 2 6 0.4) (Fig. 5); a
slightly less significant reduction was noted for fibro-
blast growth factor I (2 6 0 vs 3 6 0).
The polymer application resulted in some degree
of inflammatory reaction of the surrounding tissues
in two thirds of the animals in which it was applied;
two had clear abscess formation necessitating drain-
age. Despite these findings, the NO donor applica-
tion demonstrated an effect, and all grafts remained
open in this series of experiments.
Discussion
Neointima is, by definition, a new and usually
thickened layer that forms in response to vascular
injury. In the rabbit jugular vein it is possible to
recognize a new proliferative zone because the
normal vein wall has a single layer of endothelial
cells, a very thin layer of intima and media formed
by a few layers of smooth muscle cells, an almost
nonexistent internal elastic lamina, and a loose but
abundant layer of adventitial tissue that contains
scattered cells (Fig. 1, A).
New intimal formation has been described as an
important stage in the response to vascular injury, as
well as a precursor to stenosis and formation of
arteriosclerotic lesions.6
Several mechanisms have been postulated to ex-
plain the development of intimal hyperplasia,
among them, the influence of hemodynamic factors
such as turbulence, wall shear stresses and compli-
ance mismatch, interactions between components of
the vessel wall (endothelial cells, smooth muscle
cells), and elements of the blood (e.g., platelets,
macrophages, and leukocytes). In all of these hy-
pothesized mechanisms, the central theme has been
the initial occurrence of endothelial injury.7
The best known mitogen for smooth muscle cells
is basic fibroblast growth factor, and the best known
migration stimulator is platelet-derived growth fac-
tor.6, 7 Our attempts to study expression of platelet-
derived growth factor in this model were not suc-
cessful because at the time the experiments were
carried out, the only primary antibody available was
an antihuman rabbit-produced antibody; the sec-
ondary antibody for immunostaining has to be anti-
rabbit, and in this model it produces a very signifi-
cant background staining, making the interpretation
of the results difficult and unreliable. Little is known
about other molecules controlling the response of
vein conduits when they are exposed to arterial hemo-
dynamics in human beings or in other complex animal
species, thus our interest to study insulin-like growth
factor I and several matrix proteins expression.
Several agents have been tested experimentally and
clinically to reduce neointimal formation in injured
arteries, as well as in vein grafts. Some of these
methods have been successful in the animal model, but
when applied clinically, the results have been inconsis-
tent at best, and commonly ineffective; such is the case
of the platelet inhibitors aspirin and dipyridamole,13, 14
as well as heparin,15 steroids,16 and photodynamic
therapy of vein grafts.17 In an attempt to achieve a
more efficient control of neointimal growth, different
approaches have recently been taken, such as gene
therapy with the use of an adenovirus vector18 or
antisense oligonucleotide blockage of medial smooth
muscle cell proliferation.19 Much attention has been
given to the study of NO in the prevention of neoin-
timal formation, given its known effects on vasomotor
tone,20 platelets,21 neutrophil interaction with the en-
dothelium,10 and smooth muscle cell proliferation.11
Less is known regarding the effect of NO on smooth
muscle cell protein synthesis, including production of
collagen by these cells.
The methods used to increase the presence of NO
in the arterial wall have ranged from supplementa-
tion with the nitric oxide precursor L-arginine,22
NO-generating compounds such as S-nitroso-N-
acetylpenicillamine, and sodium nitroprusside,23 to
local delivery of NO-releasing donor compounds.24
Fig. 3. Effect of NO donor on cell density, compared with
saline, polymer, and polymer1spermine controls.
ANOVA, Analysis of variance.
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Local delivery may offer the advantage of preserving
desired regional effects on platelets, smooth muscle
cells, macrophages, and lymphocytes, as well as on
extracellular matrix proteins, while systemic effects
such as hypotension are minimized. This approach
also circumvents the rapid inactivation of NO by
hemoglobin in the circulating blood before achiev-
ing high concentrations at the target site.
Dietary fat intake and high levels of plasma lipids
have been recognized as major risk factors in the
development and progression of arteriosclerosis.
They influence both platelet and endothelial cell
function in human beings and experimental mod-
els.25 Badimon and colleagues26 have shown that
high plasma lipid levels may contribute to acute
thrombosis through a mechanism by which platelet–
vessel wall interactions are enhanced and modulated
because of changes in platelet reactivity and red
Fig. 4. Immunohistochemical studies of expression of thrombospondins in venoarterial grafts. Group 1,
saline (A); group 2, polymer (B); group 3, polymer1spermine (C); group 4, polymer1spermine/NO (D).
Note the almost complete absence of thrombospondin expression by cells in the NO-treated graft (D). n,
Neointima (media and intima); a, adventitia. (Original magnification 3 50.)
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Chaux et al. 6 0 9
blood cell shape deformation in relation to choles-
terol levels.
We have used a hypercholesterolemic rabbit
model to demonstrate the importance of the pres-
ence of vein valves in the formation of arterioscle-
rosis-like lesions in venoarterial grafts.12 In that
study we noted that thickness and area of the
neointima are increased at 4 weeks after implanta-
tion of the vein graft into the carotid circulation and
that cell proliferation peaked at that time as well.
On the basis of this experience, we decided to use a
similar model to test the effect of periadventitial
local delivery of NO in neointimal proliferation.
The histologic sections show cells surrounded by
the extracellular matrix that provide support to the
tissue (see Figs. 1 and 4). A major component of
extracellular matrix consists of various types of
collagen, fibronectin, tenascin, and thrombospon-
dins, among other protein compounds.
Fibronectin is a glycoprotein that couples in high
Fig. 5. Expression of insulin-like growth factor in venoarterial grafts. Group 1, Saline (A); group 2,
polymer (B); group 3, polymer1spermine (C); group 4, polymer1spermine/NO (D). n, Neointima (media
and intima); a, adventitia. (Original magnification 3 50.)
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proportion with polysaccharides, galactose, and
other sugars; it is common in neointima and it binds
to other proteins such as collagen and fibrin. Fi-
bronectin is involved in the spreading and locomo-
tion of cells and in the adhesion of fibroblasts to
tissue. It is also found in the a-granules of platelets,
and it may enhance their aggregation and adhesion
to mural thrombus at sites of vascular injury. Fi-
bronectin associates strongly with actin, is synthe-
sized by the fibroblast, and thus is an important
mediator of neointimal thickening. Tenascin and
thrombospondins are large-matrix glycoproteins.
Their function may be important in converting
quiescent smooth muscle cells to active forms of a
different phenotype capable of migration and pro-
liferation. The large size and multi-domain structure
of tenascin and thrombospondins suggest the pres-
ence of these proteins in the early formation of
matrix.27 The results obtained in this study indicate
that the method of perivascular delivery of an NO
donor is effective in achieving a decrease in neoin-
timal formation. The mechanism of this action is not
explained by the data obtained in this study; how-
ever, the action appears to be due to a combination
of NO donor-induced impaired mitogenesis and a
reduction of expression of several extracellular ma-
trix proteins such as thrombospondins, fibronectin,
and tenascin. These data are consistent with those of
other investigators studying vascular smooth muscle
cells.23
Because of the lack of statistical significance
between the effects of the carrier spermine alone
and the NO donor (spermine/NO), it is not possible
to conclude that NO alone was responsible for the
effects seen in the study. Without determination of
tissue levels of cyclic guanosine monophosphate (a
marker of the effect of NO), as suggested by Park
and associates,28 it is difficult to clarify this issue. We
propose that in future investigations tissue levels of
cyclic guanosine monophosphate should be mea-
sured and that other NO donors that do not include
spermine, such as DEA-NO (diethylamino-NO),
SNAP (S-nitroso-N-acetylpenicillamine), or GSMO
(nitroso-glutathione), could be used to compare
their effects with those of local perivascular delivery
of NO and to help delineate the effect of the carrier.
The inhibitory effect of the carrier spermine sug-
gested in these experiments supports the recent
findings of other researchers.29, 30 The exact mode
of action of spermine, however, continues to be a
subject of investigation. The importance and the
different roles of the extracellular matrix compo-
nents to the formation of neointimal hyperplasia
have only very recently been considered, and further
studies such as this one should increase the possi-
bility to target the process as a method to limit
neointimal hyperplasia.
The major limitation of this delivery method for
NO in human beings would be due to technical
difficulties in controlling the application of the
polymer1spermine/NO mixture and the inflamma-
tory reaction that it produces in the surrounding
tissues. Other methods of local NO delivery are
under investigation.
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Discussion
Dr. Edward D. Verrier (Seattle, Wash.). Current theo-
ries of atherosclerosis all revolve around the “endothelial
injury” theory, which is then affected by a host response
involving components of the vessel wall and elements
within the blood. The responding lesion of early intimal
proliferation is characterized by smooth muscle migration
to the intima, cellular proliferation, and extracellular
matrix elaboration. This sequence has been extensively
characterized in a number of animal models including the
rabbit jugular vein/carotid artery model used by the
authors. NO was the molecule of the year in 1992 and
continues to be studied extensively. NO has a number of
effects on the vasomotor properties of the endothelial
cells, platelet activation, neutrophil interaction, and
smooth muscle proliferation. NO should be theoretically
favorable in preventing neointimal hyperplasia. The deliv-
ery model of NO to the adventitia of the jugular vein using
the polyamine vehicle is the model chosen by these
authors.
I have a number of questions. As they noted, the major
concern of their conclusions is the fact that both spermine
and spermine with NO had an effect, and that spermine
had an independent effect. Spermine alone mixed with the
biodegradable polymer had an effect, as did the sperm-
ine/NO polymer. If the group size had been larger, the
spermine polymer would probably have reached statistical
significance by comparison with the controls. There were
no differences between the spermine polymer and sperm-
ine NO/polymers group. To show NO dependence, did
you consider other NO donor agents, such as diethyl-
amino NO, or SNAP (S-nitroso-N-acetylpenicillamine)
NO, or nitrosoglutathione, which are all NO carriers? By
using these agents and consistently showing that NO
donor agents had a greater effect than the vehicle alone,
the argument would be considerably stronger.
Dr. Chaux. You are absolutely correct. We have con-
sidered using other NO donors. Unfortunately, our labo-
ratory is in a transition period, and that work will have to
be completed in the future. There is an opportunity for
groups interested in this subject to take over this work.
Yes, there are ways to differentiate if the effects seen in
these experiments are indeed due to NO or if they are due
to spermine. I believe the effects are probably due to
combined effects. There have been recent publications on
the effects of spermine as an isolated agent on intimal
hyperplasia.
Dr. Verrier. The half-life of spermine is only 39 min-
utes. It is hard to believe that this short-term exposure to
NO had any effect on the overall development of neoin-
timal hyperplasia. If this is the case, then why wouldn’t the
infusion of sodium nitroprusside or nitroglycerin have an
effect? In fact, they probably do. However, the exposure
has to be much longer if not continuous. For years, we
have given nitroglycerin and nitroprusside postoperatively
to our patients who have had vascular and cardiac oper-
ations, and neointimal hyperplasia still develops in many
of them. The literature contains a number of studies
addressing this issue. The first involved balloon angio-
plasty on the rat aorta. The rats were then immediately
placed in living chambers where the content of air inhaled
could be controlled. Rats in the experimental group were
chronically exposed to low levels of NO; the control group
had normal air. When they were killed, the animals that
had been breathing the gas mixture with NO had no
neointimal hyperplasia, whereas the control animals did.
The investigators then took the study a step further and
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took some of the animals out of the NO environment after
some period of time and had them inspire normal air.
When the animals were later killed, the rats that had been
exposed to only NO still had no intimal hyperplasia,
whereas those that had been initially placed in the NO
environment and then moved to air did have intimal
hyperplasia. Thus the study suggests that long-term expo-
sure to NO is needed to prevent intimal hyperplasia. Early
exposure to NO may only delay the development and not
prevent the occurrence of intimal hyperplasia. Your
thoughts?
Dr. Chaux. This is a very controversial area. The
working hypothesis, which has not yet been proved, can be
considered as a first step. It is based on the possibility that
local delivery is different from systemic delivery of NO. If
local delivery can produce very high initial concentrations
and, by doing so, can stop the very initial injury changes
that occur at the endothelial as well as subendothelial and
adventitial layers, perhaps we can modify the rest of the
processes that eventually will result in neointimal hyper-
plasia. At present, this is theoretical, and I do not mean to
claim that this indeed will be the case.
Dr. Verrier. The inflammatory reaction of the carrier is
of significant concern. In fact, we are postulating that the
number of cells decreases with the NO carrier group, and
yet the inflammatory response, at least in two thirds of
those, is increased. An inflammatory response would be
expected to elicit a cellular reaction. How do you rectify
those two differences, particularly in the one third of the
animals that did not have the inflammatory response?
Was that different from those that had inflammation?
Dr. Chaux. Yes, it is surprising that the inflammatory
reaction produced by this polymer was more pronounced
in the surrounding tissues than in the graft itself. The
grafted veins were all patent, even in the presence of an
“abscess” surrounding some of them, and it was possible
to dissect the grafts easily. A significant amount of inflam-
matory reaction was noticed in the muscular layers around
the graft. We performed cell counts in the grafts four
different times and we could not find significant differ-
ences. We are merely reporting the observation without a
good explanation of why the inflammatory changes noted
were mostly in the surrounding tissues and not in the
grafts.
Dr. Verrier. How were the cell counts done, and do cell
counts measure cellular proliferation? Did you consider
using proliferating cell nuclear antigen or any other
nuclear assays of proliferation, which are shown to be
significantly more accurate than the subjective assessment
of counting cells?
Dr. Chaux. We used hematoxylin stain for nuclei. In this
series of experiments, we did not use proliferating cell
nuclear antigen, as we have done and published in the
past. After the nuclei were stained, they were counted by
means of the Optimas system and software.
Dr. Verrier. Immunocytochemistry was used to analyze
your extracellular matrix protein and growth factors.
Quantitating differences can be very difficult because
visual assessment of different intensities of stain is subjec-
tive. Could you better describe this approach? Were your
specimens randomized and were the reviewers blinded to
the protocols? How consistent were the observations
between observers?
Dr. Chaux. The specimens were not randomized and
the reviewers were blinded. One of the reviewers and
coauthors was Dr. Michael Fishbein, senior pathologist at
Cedars-Sinai. The other one was a technician in our
laboratory who also did the staining in a blinded fashion.
You are correct in saying that this is a subjective method
and that it is difficult to quantify the differences. Pathol-
ogists do accept these gradings, and there are plenty of
reports in the literature to document grading expressions
between 0 and 3. A 0 gradient means that there is no
expression at all, grade 1 is a very weak expression, grade
2 is an intermediate expression, and grade 3 corresponds
to a strong expression of either growth factors or extra-
cellular matrix proteins.
Dr. Verrier. Why did you elect to study insulin-derived
growth factor rather than platelet-derived growth factor?
Platelet-derived growth factor is the most well-character-
ized and strongest smooth muscle mitogen.
Dr. Chaux. Right. Unfortunately, there is no available
platelet-derived growth factor secondary antibody that
can be used in the rabbit model. The secondary antibodies
available for immunostaining are antirabbit, and if used in
this model they produce extensive background staining.
We searched and searched to see if there were platelet-
derived growth factor antibodies produced in another
animals that could be used in the rabbit model, and we
could not find any. We considered changing our model to
rodents or to other mammals, but that was not very
practical for us. That is the reason we did not study
platelet-derived growth factors. In trying to choose an-
other growth factor, we arbitrarily decided on insulin-
derived growth factor because its expression and effects
are less well known and the antibody is readily available
for use in this rabbit model.
Dr. Verrier. This observational study is an important
step in understanding NO influence on vascular cellular
responses. I believe we must be very careful in making any
cause-and-effect conclusions. The relationship between
endothelial activation, smooth muscle responses, matrix
effects and growth factor, cytokines and NO, or other
endothelial-derived factors, are very complex; therefore
we need to be very careful about the conclusions, partic-
ularly those between cause and effect.
Dr. David A. Fullerton (Winnetka, Ill.). I think you are
on to something here, for the following reasons. A flurry
of publications have appeared recently in the basic science
journals looking at the effects of ionized radiation on
preventing restenosis after angioplasty, and for that rea-
son there is a push to develop radioactive stents. The
surgeon’s analogy to that is to be able to provide some-
thing topical, as you have done now at the time of surgery.
I am compelled that you have used the standard model
for generating atherosclerosis. Your control data are
histologically identical to those published by other
investigators, and I am persuaded that in your treat-
ment groups, you diminished the proliferation in the
neointima.
Acknowledging that NO may or may not be the mech-
anism by which you achieved your results, from a prag-
matic standpoint, do you think it is possible to overcome
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the problems you identified in terms of just the cumber-
some nature of the polymer? It would seem to me that
some engineer ought to be able to design a readily usable
polymer that you could just drip onto the anastomosis.
Perhaps you do not even need NO in it; perhaps it is just
spermine or some other compound. Can those problems
be overcome?
Dr. Chaux. Yes, I think that they can. I believe the
saphenous vein can be modified to make it a better
conduit. To that effect, workers at Stanford are trying to
manipulate genes. We have done some of that work as
well. We have now completed a different series of exper-
iments in which an external stent is placed around the
vein; there is a plan to use low-radiation stents as well.
With respect to NO in particular, I think it is possible to
modify the method that we used. For instance, it is
possible to place a layer of some kind of different material,
with or without the stent, and deliver high concentrations
of NO to the adventitia of the vessel. I believe, as do many
others, that the adventitia is going to be extremely impor-
tant in understanding the biology of vein conduits. As Dr.
Verrier mentioned before, the initial endothelial injury is
important, but there is increasing evidence that the pro-
cess of response to vessel injury comes from the inside
layers of the vessel, as well as the outside layers. It is a
fascinating field; there is a lot of room here for young
investigators, and for others not so young, who want to
have a little fun.
The Journal of Thoracic and
Cardiovascular Surgery
March 1998
6 1 4 Chaux et al.
